Introduction {#sec1-1}
============

Stroke remains a health problem in the world and as the major cause of morbidity, mortality and disability in developing country \[[@ref1]\], \[[@ref2]\], also in Asia, Russia, East Europe \[[@ref3]\] and as multifactorial disease and complex caused by vascular, environment and genetic \[[@ref4]\], \[[@ref5]\]. The incidence of stroke increased in lower and middle-income countries. WHO predict in the year 2050, 80% of cases of stroke happened in that countries \[[@ref4]\].

Aetiology and pathogenesis of ischaemic stroke are complex and involved some risk factor \[[@ref6]\], many evidence showed the role of genetic in stroke \[[@ref4]\], but identification of the gen that related to stroke is still controversy \[[@ref7]\]. *A cohort* study showed that family history with stroke would increase the risk of stroke \[[@ref8]\], \[[@ref9]\], and case-control study in twins also related to the inherited risk \[[@ref10]\].

Over the past decades, the role of a different candidate gene in the pathogenesis of stroke has been examined in numerous association studies \[[@ref11]\]. The epidemiologic study shows the existence of basic polygene in stroke incidence and many stroke pathogenesis, they act as interactions between genetic, and others risk factors \[[@ref5]\], \[[@ref7]\], the interaction related to atherosclerosis which is major pathogenesis of stroke \[[@ref12]\]. Many gene and polymorphism have been studied as the cause of hypertension and act as a major risk factor for stroke \[[@ref13]\].

The methylenetetrahydrofolate reductase *C677T* mutation is one of the most common gene polymorphisms. Mapped to chromosomal region 1p36.3, the *MTHFR* gene spans a 2.2-kb length with 11 exons and 10 introns \[[@ref14]\] and encodes an enzyme composed of 656 amino acids \[[@ref15]\]. The product, known as MTHFR, is a critical enzyme in homocysteine metabolism. The *C677C* to *T* mutation in the catalysing region of the *MTHFR* gene may induce the displacement of alanine by valine \[[@ref16]\]. This change may lead to the thermolability of the enzyme and the inhibition of *MTHFR* activity, thus decreasing the transformation from 5,10 methylenetetrahydrofolate to 5 methyltetrahydrofolates \[[@ref11]\], which act as a co-substrate for the conversion from homocysteine to methionine \[[@ref14]\].

A lot of case-control studies have shown the role of C to T mutation in 677 nucleotides in the *MTHFR* gene; they found a significant relationships between *C677T* with hypertension in Caucasian and Asian population \[[@ref13]\]. The *MTHFR* *C677T* polymorphism has previously been found to associate with various vascular disease including stroke, hypertension and congestive heart failure \[[@ref11]\].

Prevalence *MTHFR* *C677T* relatively high in general population, while the prevalence of T allele is about 0.34 (0.29-0.39) in whites, 0.42 (0.34-0.50) in Japanese and 0.08 (0.06-0.12) in African \[[@ref17]\]. Other research shows that T allele frequency is much varied in different ethnic and country, 22.6% in the Guangxi Yao population, 32.2% in Australia, and 63.1% in Shandong \[[@ref18]\].

People with *MTHFR* 677TT gene only have 30% of enzyme activity, while the *MTHFR* *C677T* has 60% of enzyme activity compared with the wild type \[[@ref6]\]. T allele from *MTHFR* gene polymorphism is an independent risk factor of idiopathic ischaemic stroke \[[@ref19]\], and prognostic factor for cardiovascular disease \[[@ref20]\].

Genetic studies have a role in optimized stroke prevention and therapy \[[@ref9]\], also can be used to predict the risk of the disease, but the results of the studies did not mention about the type and numerous gene that act as a stroke risk factor \[[@ref7]\]. Significant improvement in the last few years about the role of genetic in stroke, giving deep knowledge about the basic molecular disease that can be used for the management patients \[[@ref21]\] and to get new therapy target \[[@ref10]\]. Identification of stroke risk factor can be modified to get stroke prevention more effective and decrease the mortality \[[@ref3]\].

This study aims to know about the role of polymorphism gen *MTHFR* *C677T* in ischaemic stroke patients with and without hypertension.

Material and Methods {#sec1-2}
====================

This study is a cross-sectional study; the sample was taken consecutively. The study was conducted with the approval of the ethics committee of the institutions involved, and informed consent was obtained from all subjects or their relatives (for comatose patients). Inclusion criteria were the presence of ischaemic stroke at the present hospital admission, age \> 18 years old; the neurological deficits were confirmed in all cases by computerised tomography (CT) scan. We analysed the *MTHFR* genotypes in subjects with ischaemic stroke. The polymorphism was classified into three groups, (1) allele CC, (2) allele CT, (3) allele TT.

A polymerase chain reaction followed by the restriction fragment length polymorphism was used to genotype the *C677T* polymorphism of *MTHFR*. The conditions of amplification and digestion have been well documented previously in our laboratory. The digested PCR products after separation on a 3% agarose gel, stained with ethidium bromide, showed one band of 198bp corresponding to the wild-type homozygous (CC), three bands of 198, 175, and 23bp for the heterozygous (CT), two bands of 175 and 23bp for the mutated homozygous (TT).

Results {#sec1-3}
=======

This study includes 106 ischaemic stroke patients were divided into two groups, with and without hypertension. A total of 55 men had an ischaemic stroke, while 51 women had an ischaemic stroke, 60 patients at the age below 60 y.o, 46 patients at the age above 60 y.o, Bataknese 33 patients, family history was found in 32 patients.

The differences in the characteristics of patients with and without hypertension are shown in [Table 1](#T1){ref-type="table"}.

###### 

Distribution of characteristic frequency ischaemic stroke with and without hypertension

  Variable         Category     Ischaemic Stroke                               
  ---------------- ------------ ------------------ ------ ------ ------ ------ ------
  Age              \< 60 y.o    30                 28,3   30     28.3   60     56.6
  \> 60 y.o        23           21.7               23     21.7   46     43.4   
  Gender           Female       25                 23.6   26     24.5   51     48.1
  Male             28           26.4               27     25.4   55     51.9   
  Ethnicity         Bataknese   33                 31.1   29     27.3   62     58.4
   Javanese        11           10.4               10     9.43   21     19.8   
   Acehnese        4            3.77               3      2.83   7      6.60   
   Minangnese      2            1.88               2      1.88   3      2.83   
   Melayumese      2            1.88               9      8.49   11     10.3   
   Niasnese        1            0.94               \-     \-     1      0.94   
  Family history                32                 30.1   17     16.0   49     46.2

This study found that among 106 patients ischaemic stroke with hypertension and without hypertension, the wild-type homozygous (CC) was found in 76 patients; 71.7% (32 patients with hypertension, 43 patients without hypertension). The heterozygous (CT) was found in 26 patients; 24.5% (16 patients with hypertension, 10 patients without hypertension). The mutated homozygous (TT) was found only in ischaemic stroke patients with hypertension (5 patients).

Fisher exact test was done for this variable category; the result showed a significant correlation (p = 0.035) ([Table 2](#T2){ref-type="table"}).

###### 

Distribution of frequency polymorphism ischaemic stroke with and without hypertension

  Variable       Category   Ischaemic Stroke   p-value[\*](#t2f1){ref-type="table-fn"}                               
  -------------- ---------- ------------------ ----------------------------------------- ------ ------ ------ ------ -------
  Polymorphism   CC         32                 60.3                                      43     81.1   76     71.7   0.035
  CT             16         30.2               10                                        18.9   26     24.5          
  TT             5          9.5                0                                         0      5      3.8           

Fisher Exact Test

Discussion {#sec1-4}
==========

Stroke is a common complex trait and does not follow Mendelian pattern of inheritance: Gene--gene or gene-environment interactions may be responsible for the complex trait. How the interactions contribute to stroke is still under research \[[@ref12]\].

Now we know single polymorphism may have a weak effect on the risk of stroke when analysed individually, but their influence may be more pronounced in the presence of a permissive background. Many cases of stroke are due to a complex interaction between lifestyle factors and genetic susceptibilities. Genetic predisposition for stroke may result from synergistic co effects \[[@ref11]\].

Many studies have shown that T allele frequencies in different ethnicities and countries vary widely. The Guangxi Yao population rate was 22/6%, and in Australia, it was 32.2 %. The Yang *et al*., the study of 15,357 Han patients found that the mutation frequency in Hainan was the lowest with T allele of 245 and in Shandong it was the highest (63.1%) \[[@ref18]\].

This study found that polymorphism *C677T* is more frequent in ischaemic stroke patients with hypertension (16 patients), and all the patient with 677TT genotype are an ischaemic stroke with hypertension (5 patients),

This gene is responsible for producing *Methylenetetrahydrofolate reductase* (MTHFR) enzyme that functional. The function of this enzyme is to transform 5, 10 methylenetetrahydrofolates to 5 methyltetrahydrofolates \[[@ref22]\]. The Val form of *MTHFR* encoded by 677 T allele is thermolabile and has reduced enzymatic activity \[[@ref23]\]. The mutated homozygous (TT) is the risk of thrombotic disease in young age \[[@ref24]\].

The result of this study showed a significant correlation between the polymorphism and ischaemic stroke with and without hypertension (p = 0.035).

There is a strong association between polymorphism gen *MTHFR* with atherosclerosis; even the mechanism of it is indirect. Patients with *MTHFR* genotype 677TT, have a vascular occlusion, and infarct, had increased level of blood homocysteine. Those are the reason for the association between polymorphism and hypertension \[[@ref12]\].

In conclusion, polymorphism *MTHFR* *C677T* has an important role in hypertension and ischaemic stroke, because both of the diseases is caused by atherosclerotic vascular disease.

There are several limitations to our study. First, the study enrolled hospital-based stroke patients rather than patients from a community based general population. Secondly, this study did not collect data on other several major risk factors of ischaemic stroke.
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